TACSTD2 and prostate carcinoma: Taken together, our findings suggest that TROP2-expressing cells are detectable across all prostate cancer stages but that differences of TROP2 expression levels among patients may highlight a worse prognosis for prostate cancer patients, particularly for those diagnosed with early stage tumors.